Charles River Laboratories (CRL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jul, 2026Executive summary
Q1 2025 revenue was $984.2 million, down 2.7% year-over-year, but organic revenue fell only 1.8%, outperforming expectations due to strong DSA segment results and improved bookings.
Non-GAAP EPS rose 3.1% to $2.34, while GAAP EPS dropped to $0.50, reflecting restructuring and one-time charges; net income available to common shareholders was $25.5 million, down from $67.3 million.
Cost-saving initiatives and restructuring drove non-GAAP operating margin up 60 bps to 19.1%, while GAAP margin fell to 7.6% due to lower revenue and accelerated amortization.
$350 million in stock repurchases were completed in Q1 2025, with $549.3 million remaining authorized.
Strategic review and board refresh launched with Elliott Investment Management to unlock value.
Financial highlights
Service revenue declined 2.3% to $797.9 million; product revenue fell 4.3% to $186.2 million year-over-year.
Non-GAAP operating margin rose to 19.1% (up 60 bps); GAAP margin dropped to 7.6% (down 490 bps); free cash flow was $112.4 million, more than doubling year-over-year.
Capital expenditures were $59.3 million, down from $79.1 million year-over-year.
Cash and cash equivalents at quarter-end were $229.4 million; debt at $2.5 billion, with 60% fixed rate.
Gross leverage ratio was 2.5x; net leverage 2.4x; interest coverage ratio 6.23x.
Outlook and guidance
2025 organic revenue guidance improved to a 4.5% to 2.5% decline; non-GAAP EPS guidance raised to $9.30–$9.80; GAAP EPS guidance is $4.30–$4.85.
DSA organic revenue expected to decline mid-single digits, improved from prior outlook; RMS outlook moderated to flat to slightly positive growth.
Manufacturing revenue expected to be flat organically for 2025; margin expected to rebound as volumes improve.
Q2 revenue expected to decline low to mid-single digits year-over-year, with sequential EPS improvement.
Management targets $225 million in annualized cost savings from restructuring, with $175 million impacting 2025.
Latest events from Charles River Laboratories
- 2026 guidance projects margin improvement and EPS growth despite flat revenue.CRL
Q4 20259 Jul 2026 - Robust demand, cost discipline, and innovation drive stable margins and long-term growth.CRL
Morgan Stanley 23rd Annual Global Healthcare Conference9 Jul 2026 - Strategic review advances as stable core businesses offset biotech funding headwinds.CRL
Baird Global Healthcare Conference 20259 Jul 2026 - Growth and innovation in research, manufacturing, and ESG drive industry leadership.CRL
The 44th Annual William Blair Growth Stock Conference9 Jul 2026 - 2024 outlook cut as demand weakens; cost actions and $1B buyback support margins.CRL
Q2 20248 Jul 2026 - Q3 revenue fell 1.6% but cash flow hit a record as restructuring and cost savings advanced.CRL
Q3 20248 Jul 2026 - Biotech demand is recovering, tech investments grow, and China rises as a key innovation hub.CRL
Barclays 28th Annual Global Healthcare Conference8 Jul 2026 - Q3 2025 saw stable demand, new $1B buyback, and narrowed guidance amid sector uncertainty.CRL
Q3 20258 Jul 2026 - New strategy emphasizes margin gains, AI integration, and growth as demand stabilizes.CRL
Jefferies Global Healthcare Conference 20263 Jun 2026